SETD2 and acute myeloid leukemia: Recently, SETD2 was identified as tumor suppressor, as loss-of-function mutation with SETD2 has been discovered in various tumors, including ccRCC, lung adenocarcinoma, gliomas, AML, ALL, and mastocytosis [12, 28–32].